Acorn AI
Acorn AI Offerings
From Trial to Launch
Whether it’s through better trial planning and design, the development of a Synthetic Control Arm® or positioning a new drug for launch, Acorn AI is dedicated to ensuring that new possibilities are always on the horizon.
Our unparalleled clinical trial data combined with a unified platform, advanced analytics and deep human expertise uncover breakthrough insights for you to make confident decisions while pursuing the innovations that propel science and healthcare forward.”
Acorn AI Solutions
From planning to launch, we are your collaborative partner — pushing the innovations realized through unparalleled clinical trial data, deep industry and human expertise, advanced analytics and predictive modeling.
Intelligent Trials
Gain a competitive edge in trial planning and enrollment through real time data and analytics.
Integrated Evidence
Accelerate approvals using advanced analytics and our unparalleled historical clinical trial database to enhance insights, eg. via Synthetic Control Arm
Connected Patient
Enable collaboration and precision in patient care by connecting the new digital health data management ecosystem.
Commercial Data Solutions
Maximize pharmaceutical brand success with powerful commercial data management and insights.
Acorn AI Labs
New York, Boston
Where our data science teams work shoulder-to-shoulder with clients to tackle the toughest problems in Life Sciences — opening the door to more effective and tailored treatments.
The Acorn AI Labs model is designed to accelerate data science capabilities and rapidly unlock business value.
Who We Are
At Medidata Acorn AI, there are hundreds of incessantly curious, multi-disciplinary experts who equip you with the vital data and tools you need to find new innovative approaches to clinical trials and to rethink the limits of what is possible — because today’s challenges demand it.
MIT Technology Review
White Paper
What if researchers didn’t need to recruit a control group at all and could offer the experimental treatment to everyone who agreed to be in the study? Celsion, a biotechnology company that develops next-generation chemotherapy and immunotherapy agents, is exploring such an approach with Medidata.